Riltozinameran

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameRiltozinameran
Drug Alias NameBNT162b2 OMI vaccineCOVID-19 Omicron-Modified Vaccine（Biontech）
ClassificationVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth AfricaGermany +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiontech SePfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncBiontech Se
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A